Please Wait.....
Report
Europe Gene Therapy Market - Industry Trends and Forecast to 2030
Market Report I 2023-03-01 I 149 Pages I Data Bridge Market Research
Europe gene therapy market is projected to register a CAGR of 18.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Europe Gene Therapy Market, By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, and Rest of Europe) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the gene therapy market are:
- Rising demand of personalized medicine
- Rising prevalence of genetic disorders
- Novel approaches of gene therapy
Market Players:
The key market players for Europe gene therapy market are listed below:
- AGC Biologics
- Amgen, Inc.
- AnGes, Inc
- Biogen
- Bristol Myers Squibb Company
- CHIESI Farmaceutici S.p.A.
- Janssen Pharmaceuticals, Inc.
- Kite Pharma (a subsidiary of Gilead Sciences, Inc.)
- Mallinckrodt.
- Novartis AG
- Orchard Therapeutics plc.
- Oxford Biomedica
- Spark Therapeutics, Inc.
- uniQure NV.
TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF THE EUROPE GENE THERAPY MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 MARKET END USER COVERAGE GRID 32
2.8 PRODUCT LIFELINE CURVE 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 41
4.2 PORTER FIVE ANALYSIS 42
5 UPDATE ON GERMLINE GENE THERAPY 43
5.1 GERMLINE GENE THERAPY 43
6 EUROPE GENE THERAPY MARKET, MO 44
6.1 DRIVERS 46
6.1.1 NOVEL APPROACHES TO GENE THERAPY 46
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 46
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 47
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 48
6.2 RESTRAINTS 48
6.2.1 HIGH COST OF GENE THERAPY 48
6.2.2 ETHICAL AND SAFETY CONCERNS 49
6.2.3 COMPLEXITY OF GENE THERAPY 49
6.3 OPPORTUNITIES 50
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 50
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 50
6.4 CHALLENGES 51
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 51
6.4.2 LONG-TERM SAFETY AND EFFICACY 51
7 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE 52
7.1 OVERVIEW 53
7.2 VIRAL VECTOR 56
7.2.1 ADENOVIRUS 57
7.2.2 RETROVIRUS 57
7.2.3 LENTIVIRUS 57
7.2.4 ADENO-ASSOCIATED VIRUS 57
7.2.5 VACCINIA VIRUS 57
7.2.6 HERPES SIMPLEX VIRUS 57
7.2.7 OTHERS 57
7.3 NON-VIRAL VECTOR 57
7.3.1 LIPOFECTION 58
7.3.2 INJECTION OF NAKED DNA 58
8 EUROPE GENE THERAPY MARKET, BY METHOD 59
8.1 OVERVIEW 60
8.2 EX-VIVO 63
8.3 IN-VIVO 63
9 EUROPE GENE THERAPY MARKET, BY APPLICATION 65
9.1 OVERVIEW 66
9.2 ONCOLOGICAL DISORDERS 69
9.3 CARDIOVASCULAR DISEASES 69
9.4 INFECTIOUS DISEASES 70
9.5 RARE DISEASES 71
9.6 NUEROLOGICAL DISORDERS 72
9.7 OTHER DISEASES 73
10 EUROPE GENE THERAPY MARKET, BY END USER 74
10.1 OVERVIEW 75
10.2 CANCER INSTITUTES 78
10.3 HOSPITALS 78
10.4 RESEARCH INSTITUTES 79
10.5 OTHERS 80
11 EUROPE GENE THERAPY MARKET, BY REGION 81
11.1 EUROPE 82
11.1.1 GERMANY 88
11.1.2 FRANCE 90
11.1.3 U.K. 92
11.1.4 ITALY 94
11.1.5 SPAIN 96
11.1.6 RUSSIA 98
11.1.7 TURKEY 100
11.1.8 NETHERLANDS 102
11.1.9 BELGIUM 104
11.1.10 SWITZERLAND 106
11.1.11 REST OF EUROPE 108
12 EUROPE GENE THERAPY MARKET, COMPANY LANDSCAPE 109
12.1 COMPANY SHARE ANALYSIS: EUROPE 109
13 COMPANY PROFILES 110
13.1 BIOGEN 110
13.1.1 COMPANY SNAPSHOT 110
13.1.2 REVENUE ANALYSIS 110
13.1.3 COMPANY SHARE ANALYSIS 111
13.1.4 SWOT ANALYSIS 111
13.1.5 PRODUCT PORTFOLIO 112
13.1.6 RECENT DEVELOPMENT 112
13.2 KITE PHARMA 113
13.2.1 COMPANY SNAPSHOT 113
13.2.2 REVENUE ANALYSIS 113
13.2.3 COMPANY SHARE ANALYSIS 114
13.2.4 SWOT ANALYSIS 114
13.2.5 PRODUCT PORTFOLIO 115
13.2.6 RECENT DEVELOPMENT 115
13.3 NOVARTIS AG 116
13.3.1 COMPANY SNAPSHOT 116
13.3.2 REVENUE ANALYSIS 116
13.3.3 COMPANY SHARE ANALYSIS 117
13.3.4 SWOT ANALYSIS 117
13.3.5 PRODUCT PORTFOLIO 118
13.3.6 RECENT DEVELOPMENTS 118
13.4 BRISTOL-MYERS SQUIBB COMPANY. 119
13.4.1 COMPANY SNAPSHOT 119
13.4.2 REVENUE ANALYSIS 119
13.4.3 COMPANY SHARE ANALYSIS 120
13.4.4 SWOT ANALYSIS 120
13.4.5 PRODUCT PORTFOLIO 121
13.4.6 RECENT DEVELOPMENT 121
13.5 OXFORD BIOMEDICA 122
13.5.1 COMPANY SNAPSHOT 122
13.5.2 REVENUE ANALYSIS 122
13.5.3 COMPANY SHARE ANALYSIS 123
13.5.4 SWOT ANALYSIS 123
13.5.5 PRODUCT PORTFOLIO 124
13.5.6 RECENT DEVELOPMENTS 124
13.6 AGC BIOLOGICS 125
13.6.1 COMPANY SNAPSHOT 125
13.6.2 PRODUCT PORTFOLIO 125
13.6.3 RECENT DEVELOPMENT 125
13.7 ANGES, INC 126
13.7.1 COMPANY SNAPSHOT 126
13.7.2 REVENUE ANALYSIS 126
13.7.3 PRODUCT PORTFOLIO 127
13.7.4 RECENT DEVELOPMENT 127
13.8 AMGEN INC. 128
13.8.1 COMPANY SNAPSHOT 128
13.8.2 REVENUE ANALYSIS 128
13.8.3 PRODUCT PORTFOLIO 129
13.8.4 RECENT DEVELOPMENT 129
13.9 BLUEBIRD BIO, INC. 130
13.9.1 COMPANY SNAPSHOT 130
13.9.2 PRODUCT PORTFOLIO 130
13.9.3 RECENT DEVELOPMENT 130
13.10 CHIESI FARMACEUTICI S.P.A 131
13.10.1 COMPANY SNAPSHOT 131
13.10.2 REVENUE ANALYSIS 131
13.10.3 PRODUCT PORTFOLIO 132
13.10.4 RECENT DEVELOPMENT 132
13.11 DENDREON PHARMACEUTICALS LLC 133
13.11.1 COMPANY SNAPSHOT 133
13.11.2 PRODUCT PORTFOLIO 133
13.11.3 RECENT DEVELOPMENT 133
13.12 ENZYVANT THERAPEUTICS GMBH 134
13.12.1 COMPANY SNAPSHOT 134
13.12.2 RODUCT PORTFOLIO 134
13.12.3 RECENT DEVELOPMENT 134
13.13 FERRING B.V. 135
13.13.1 COMPANY SNAPSHOT 135
13.13.2 PRODUCT PORTFOLIO 135
13.13.3 RECENT DEVELOPMENT 135
13.14 JANSSEN PHARMACEUTICALS, INC. 136
13.14.1 COMPANY SNAPSHOT 136
13.14.2 PRODUCT PORTFOLIO 136
13.14.3 RECENT DEVELOPMENT 136
13.15 MALLINCKRODT. 137
13.15.1 COMPANY SNAPSHOT 137
13.15.2 REVENUE ANALYSIS 137
13.15.3 PRODUCT PORTFOLIO 138
13.15.4 RECENT DEVELOPMENT 138
13.16 ORCHARD THERAPEUTICS PLC. 139
13.16.1 COMPANY SNAPSHOT 139
13.16.2 REVENUE ANALYSIS 139
13.16.3 PRODUCT PORTFOLIO 140
13.16.4 RECENT DEVELOPMENT 140
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 141
13.17.1 COMPANY SNAPSHOT 141
13.17.2 PRODUCT PORTFOLIO 141
13.17.3 RECENT DEVELOPMENT 141
13.18 SIBONO 142
13.18.1 COMPANY SNAPSHOT 142
13.18.2 PRODUCT PORTFOLIO 142
13.18.3 RECENT DEVELOPMENT 142
13.19 SPARK THERAPEUTICS, INC. 143
13.19.1 COMPANY SNAPSHOT 143
13.19.2 PRODUCT PORTFOLIO 143
13.19.3 RECENT DEVELOPMENT 143
13.20 UNIQURE NV. 144
13.20.1 COMPANY SNAPSHOT 144
13.20.2 REVENUE ANALYSIS 144
13.20.3 PRODUCT PORTFOLIO 145
13.20.4 RECENT DEVELOPMENT 145
14 QUESTIONNAIRE 146
15 RELATED REPORTS 149
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security